Newsroom

The Ivy Brain Tumor’s goal is to try to speed advances into the clinic by testing potential therapies on tumor samples taken from patients who are currently battling glioblastoma—an approach its researchers hope will shed some light on the potential of Karyopharm’s new drug in treating the disease.

The Ivy Brain Tumor Center at the Barrow Neurological Institute has announced a partnership with Karyopharm Therapeutics (Nasdaq:KPTI) to accelerate the treatment of brain cancer.

"Our philosophy is that it is as important to fail fast as it is to succeed quickly," said Nader Sanai, the director of the Ivy Brain Tumor Center at Barrow Neurological Institute.

In the heart of Phoenix, a team of doctors is vigilantly working to find a cure for Glioblastoma (GBM), the deadliest form of brain cancer.

The Ben & Catherine Ivy Foundation has provided a $50 million grant to Ivy Brain Tumor Center —these funds are powering the Phase 0 research in an attempt to combat brain cancer.

Ivy Brain Tumor Center at The Barrow Neurological Institute has launched a program that offers phase 0 trials to accelerate the drug approval process for patients with glioblastoma.

In this edition of The Onco’Zine Brief Peter Hofland talks with Dr. Nader Sanai an internationally-recognized neurosurgical oncologist with clinical and research expertise in the treatment of all brain tumors, including glioblastoma, the most aggressive cancer that begins within the brain.

In Bret Stetka's latest piece for the Scientific American, Dr. Nader Sanai weighs in on the challenges of treating glioblastoma and how our accelerated Phase 0/2 clinical trials are delivering new therapeutic options for patients facing the fight of their lives.

The Ivy Brain Tumor Center at Barrow Neurological Institute is taking a bold approach by using Phase 0 testing in patient clinical trials.

There's a glimmer of hope in treating the deadliest form of brain cancer, thanks to a drug trial happening right here in the Valley.